CA2346152A1 - Procede pour favoriser l'autorenouvellement et transduction genique amelioree des cellules souches hematopoietiques par des inhibiteurs de desacetylase de l'histone - Google Patents
Procede pour favoriser l'autorenouvellement et transduction genique amelioree des cellules souches hematopoietiques par des inhibiteurs de desacetylase de l'histone Download PDFInfo
- Publication number
- CA2346152A1 CA2346152A1 CA002346152A CA2346152A CA2346152A1 CA 2346152 A1 CA2346152 A1 CA 2346152A1 CA 002346152 A CA002346152 A CA 002346152A CA 2346152 A CA2346152 A CA 2346152A CA 2346152 A1 CA2346152 A1 CA 2346152A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- stem cells
- histone deacetylase
- hematopoietic
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur un procédé visant à favoriser l'autorenouvellement des cellules souches et consistant à exposer une population de cellules souches, notamment les cellules souches hématopoïétiques, à une dose effective d'un inhibiteur de désacétylase de l'histone, notamment la trichostatine ou la chlamydocine. L'invention porte également sur l'utilisation des inhibiteurs de désacétylase de l'histone permettant d'accroître le nombre des cellules souches ayant subi une transduction.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17363398A | 1998-10-16 | 1998-10-16 | |
US13247699P | 1999-05-04 | 1999-05-04 | |
US60/132,476 | 1999-05-04 | ||
US09/173,633 | 1999-05-04 | ||
PCT/EP1999/007741 WO2000023567A2 (fr) | 1998-10-16 | 1999-10-14 | Procede pour favoriser l'autorenouvellement et transduction genique amelioree des cellules souches hematopoietiques par des inhibiteurs de desacetylase de l'histone |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2346152A1 true CA2346152A1 (fr) | 2000-04-27 |
Family
ID=26830391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002346152A Abandoned CA2346152A1 (fr) | 1998-10-16 | 1999-10-14 | Procede pour favoriser l'autorenouvellement et transduction genique amelioree des cellules souches hematopoietiques par des inhibiteurs de desacetylase de l'histone |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1129175A2 (fr) |
JP (1) | JP2002527101A (fr) |
AU (1) | AU6339399A (fr) |
CA (1) | CA2346152A1 (fr) |
WO (1) | WO2000023567A2 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5032669A (en) * | 1990-05-01 | 1991-07-16 | University Of Massachusetts At Amherst | Liquid crystalline polyesters formed by reaction of bis(hydroxyalkoxy) biphenyls with terephthaloyl chloride |
AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
DE10162080A1 (de) * | 2001-12-10 | 2003-06-26 | Albrecht Mueller | Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential |
DE60331297D1 (de) | 2002-03-07 | 2010-04-01 | Univ Delaware | Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff |
ATE497533T1 (de) * | 2004-05-05 | 2011-02-15 | Zorica Becker-Kojic | Verwendung von glykoprotein aca antikörper zur gewinnung oder erhaltung von pluripotenten nicht- embryonalen stammzellen |
ATE527341T1 (de) * | 2004-10-27 | 2011-10-15 | Univ Bruxelles | Hepatische differenzierung von stammzellen |
CN101263121A (zh) | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
AU2006325975B2 (en) | 2005-12-13 | 2011-12-08 | Kyoto University | Nuclear reprogramming factor |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
KR101661940B1 (ko) | 2008-05-02 | 2016-10-04 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 핵 초기화 방법 |
JP5010760B2 (ja) | 2010-10-05 | 2012-08-29 | タカラバイオ株式会社 | ウイルスベクターの製造方法 |
SG10201602423TA (en) | 2011-09-30 | 2016-05-30 | Bluebird Bio Inc | Compounds For Improved Viral Transduction |
WO2013141133A1 (fr) | 2012-03-22 | 2013-09-26 | タカラバイオ株式会社 | Procédé de production de vecteur viral |
WO2013146480A1 (fr) * | 2012-03-29 | 2013-10-03 | タカラバイオ株式会社 | Procédé d'introduction de gène |
JP6551963B2 (ja) * | 2014-05-14 | 2019-07-31 | 国立大学法人京都大学 | 巨核球前駆細胞の製造方法 |
WO2018088821A1 (fr) * | 2016-11-10 | 2018-05-17 | 울산대학교 산학협력단 | Composition favorisant l'activité des cellules souches, comprenant un inhibiteur d'histone désacétylase et un facteur d'amorçage en tant que principes actifs |
KR102097191B1 (ko) * | 2016-11-10 | 2020-04-06 | 울산대학교 산학협력단 | 히스톤 탈아세틸화 저해제 및 프라이밍 인자를 유효성분으로 포함하는 줄기세포 활성 촉진용 조성물 |
WO2021207673A1 (fr) * | 2020-04-09 | 2021-10-14 | The Regents of the University of Colorodo, a body corporate | Compositions, méthodes et utilisations pour production de cellules souches hématopoïétiques (csh) |
EP4146797A1 (fr) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Traitement pour les maladies neurodégénératives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ307995A3 (en) * | 1993-05-24 | 1996-10-16 | Immunex Corp | Ligands for flt3 receptors |
US6060052A (en) * | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
EP0827742A1 (fr) * | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Utilisation des inhibiteurs de l'histone déacétylase pour le traitement de la fibrose ou de la cirrhose |
-
1999
- 1999-10-14 CA CA002346152A patent/CA2346152A1/fr not_active Abandoned
- 1999-10-14 EP EP99950725A patent/EP1129175A2/fr not_active Withdrawn
- 1999-10-14 JP JP2000577279A patent/JP2002527101A/ja active Pending
- 1999-10-14 WO PCT/EP1999/007741 patent/WO2000023567A2/fr not_active Application Discontinuation
- 1999-10-14 AU AU63393/99A patent/AU6339399A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU6339399A (en) | 2000-05-08 |
EP1129175A2 (fr) | 2001-09-05 |
WO2000023567A3 (fr) | 2000-07-27 |
WO2000023567A2 (fr) | 2000-04-27 |
JP2002527101A (ja) | 2002-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2346152A1 (fr) | Procede pour favoriser l'autorenouvellement et transduction genique amelioree des cellules souches hematopoietiques par des inhibiteurs de desacetylase de l'histone | |
US5928638A (en) | Methods for gene transfer | |
US7416887B2 (en) | Methods for use of MPL ligands with primitive human stem cells | |
Brandt et al. | Ex vivo expansion of autologous bone marrow CD34+ cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons | |
Gori et al. | Endothelial cells promote expansion of long-term engrafting marrow hematopoietic stem and progenitor cells in primates | |
AU755344B2 (en) | Expanded and genetically modified populations of human hematopoietic stem cells | |
US7494807B2 (en) | Mammalian megakaryocyte progenitor cell | |
US20030044978A1 (en) | Expanded and genetically modified populations of human hematopoietic stem cells | |
Crooks et al. | IL-3 increases production of B lymphoid progenitors from human CD34+ CD38− cells | |
Liu et al. | Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34+ NOD/SCID-repopulating cells | |
AU2002301459B2 (en) | Expanded and genetically modified populations of human hematopoietic stem cells | |
Björgvinsdóttir et al. | Efficient oncoretroviral transduction of extended long-term culture-initiating cells and NOD/SCID repopulating cells: enhanced reconstitution with gene-marked cells through an ex vivo expansion approach | |
US20100209396A1 (en) | Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells | |
Nolta et al. | Human hematopoietic cell culture, transduction, and analyses | |
WO1997012052A1 (fr) | Transduction de cellules hematopoietiques par vecteur viral et lipide cationique | |
Jurecic et al. | Human Hematopoietic Cells for Gene Therapy | |
Conneally | Genetic modification of human hematopoietic stem cells | |
Chu | Effect of c-kit and flt-3 overexpression on primitive hematopoietic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |